Axisresearch
List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Sorted by Name
Publishers
Countries
Australia & New Zealand Diagnostic Imaging Equipment Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 80 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 80 pages
- Published: 07-06-2019
Market Overview
Diagnostic imaging is the process where the internal structure of human body is viewed using the electromagnetic radiation, for accurate diagnosis of the patient. The diagnostic imaging uses radiations to diagnose and treat the diseases. There are various modalities in the medical imaging, the most common ones being the CT scan and MRI systems. The market studied is driven by several factors, such as growing technological advancements, including handheld X-ray and upright MRI, and increasing interest among researchers regarding medical imaging equipment. Additionally, increase in chronic diseases and increasing government funding pertaining to diagnostic imaging studies are also responsible to drive the growth of the market studied.
Scope of the Report
This report includes an in-depth study of the Australia & New Zealand diagnostic imaging equipment market (henceforth, referred to as the market studied). Diagnostic imaging is used to take images of the internal structure of human body, using electromagnetic radiation, for accurate diagnosis of the patient. There are various modalities in medical imaging, the most common ones being CT scan and MRI systems.
Key Market Trends
X-ray Equipment Segment Captures the Largest Market Share and is Expected to Retain its Dominance over the Forecast Period
An X-ray is a non-invasive medical test that helps physicians diagnose and treat medical conditions. Imaging with X-rays involves exposing a part of the body to a small dose of ionizing radiation to produce pictures of the inside of the body. Chest X-rays are the most frequently ordered imaging test in Australian general practice. They were generally accounted for 8.3% of all imaging tests ordered by general practitioners in 2013and 14. In addition, there is also a rising need for radiographers in Australia that is expected to boost the Australian market. Recently, in 2018, the New Zealand scientists have been found performing the first 3-D, color X-ray on a human, using a technique that promises to improve the field of medical diagnostics. Hence, these technologies are also being commercialized by the New Zealand company, MARS Bioimaging, and may increase the overall market.
Competitive Landscape
The presence of major market players, such as Canon Medical Systems Ltd, Carestream Health, GE Healthcare, Koninklijke Philips NV, and Siemens Healthineers, is expected to increase the overall market competition. Companies are trying to gain a sustainable competitive advantage through innovation, while maintaining their consumer base through interactive upgrades in product segments. There is significant competition on the basis of product innovation, connectivity, and ease of operation in the portable diagnostic imaging equipment segment.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Awareness Regarding Preventive Care
4.2.2 Technological Advancements
4.2.3 Growth in the Incidences of Various Diseases
4.3 Market Restraints
4.3.1 High Cost of Advanced Diagnostic Imaging Devices
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Product Type
5.1.1 X-ray Equipment
5.1.2 Ultrasound
5.1.3 Magnetic Resonance Imaging (MRI)
5.1.4 Mammography
5.1.5 Computed Tomography
5.1.6 Nuclear Medicine
5.1.6.1 Positron Emission Tomography (PET)
5.1.6.2 Single Photon Emission Computerized Tomography (SPECT)
5.2 Application
5.2.1 Cardiology
5.2.2 Oncology
5.2.3 Neurology
5.2.4 Orthopedics
5.2.5 Other Applications
5.3 End Users
5.3.1 Hospital
5.3.2 Diagnostic Center
5.3.3 Other End Users
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Canon Medical Systems Ltd
6.1.2 Carestream Health
6.1.3 Esaote
6.1.4 Fujifilm Holdings Corporation
6.1.5 GE Healthcare
6.1.6 Hitachi Medical Corporation
6.1.7 Hologic Inc.
6.1.8 Koninklijke Philips NV
6.1.9 Siemens Healthcare GmbH
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Product Type
X-ray Equipment
Ultrasound
Magnetic Resonance Imaging (MRI)
Mammography
Computed Tomography
Nuclear Medicine
Positron Emission Tomography (PET)
Single Photon Emission Computerized Tomography (SPECT)
Application
Cardiology
Oncology
Neurology
Orthopedics
Other Applications
End Users
Hospital
Diagnostic Center
Other End Users
Basal Insulin (Long-Acting Insulin) Market (2012 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 100 pages | Published: 12-06-2019 |
- Healthcare
- Mordor Intelligence
- 100 pages
- Published: 12-06-2019
Market Overview
The global basal insulin market is expected to register a CAGR of 8.2% during the forecast period of 2019–2024, the market is estimated to reach USD 11.4 billion by 2019.
Diabetes is generally considered as a lifestyle disease. Over time, incidences of the disease have increased, with the increase in population around the world.
Approximately, 100 million people around the world need insulin, including all the people living with Type 1 diabetes and between 10-25% of people with Type 2 diabetes.
Basal insulin is the most widely used insulin among diabetic patients because of its long-acting effect. Lantus tops the market, and the segment had more than 50% market share in 2017. Many countries have come up with the biosimilars of insulin since 2015.
Although insulin has been used in the treatment of diabetes for over 90 years, globally, more than half of those who need insulin today still cannot afford and access it. People with Type 1 diabetes need insulin therapy, and the treatment focuses on managing blood sugar levels with insulin, diet, and lifestyle to prevent complications.
Scope of the Report
The market is segmented by product (lantus, levemir, tresiba, toujeo, basaglar, and biosimilar glargines) and geography.
Key Market Trends
Insulin Glargine Market Access has Widened
Lantus (insulin glargine) is the first long-acting insulin brought into the market by Sanofi. The product was approved for medical use in the United States in 2000.
Lantus’ reach was high among patients across different geographical regions, and it is one of the most top-selling drugs for Sanofi, which is exported to more than 100 countries.
As of 2015, Lantus market share was around USD 7 billion. However, patent protection for Lantus expired in most countries in 2015. Insulin glargine from competitor Eli Lilly became available in most countries during 2015, under the brand names Basaglar (as a follow-on in the United States) and Abasaglar (as a biosimilar in the European Union).
In 2015, Sanofi launched the extended version of Lantus as Toujeo with 300U/mL strength.
In less stringent regulatory environments, such as India, China, Mexico, and Peru, several biosimilar insulin already exist at lower prices. In India, a glargine biosimilar was first introduced by Biocon in 2011 at a cost that was 40% lower than Lantus. More recently, Lupin Ltd, in agreement with LG Life Sciences, launched its biosimilar ‘Basugine’ in 2014.
In China, follow-on biologics Basalin (Gan and Lee Pharmaceuticals, Beijing) ranked second in the Chinese glargine market, and occupied a 40% share, after Lantus, in 2017.
The United States Leads the Global Basal Insulin Market
In the global basal insulin market, the United States held 65.6% market share in 2017. Lantus is the top-selling drug in the country and occupies 49% market share, followed by Levemir, Tresiba, Toujeo, and Basaglar.
The sale of Lantus is expected to decrease during the forecast period, due to the presence biosimilars Basaglar and Toujeo (which are the extended versions of Lantus).
The other biosimilar of Lantus (insulin glargine) is Lusduna from Merck, which was tentatively approved by the FDA in the United States. However, despite a favorable nod from the FDA, Merck decided to discontinue Lusduna because of “anticipated pricing and cost of production”.
Tresiba, launched by Novo Nordisk in 2016, received encouraging feedback from the patients and is expected to show tremendous growth during the forecast period (2019-2024) due to its ultra-long-acting effect. The levemir segment is decreasing due to the switch of patients to Tresiba.
Competitive Landscape
The global basal insulin market is consolidated, with three major manufacturers holding a global market presence, and the remaining manufacturers confining to the other local or region-specific manufacturers.
Mergers and acquisitions that happened between the players in the recent past helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim together have an alliance in developing and commercializing Basaglar (insulin glargine).
Biocon collaborated with Mylan to develop Semglee (insulin glargine biosimilar).
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.1.1.1 Lantus
5.1.1.2 Levemir
5.1.1.3 Toujeo
5.1.1.4 Tresiba
5.1.1.5 Basaglar
5.1.1.6 Insulin Glargine Biosimilars
5.2 Geography
5.2.1 North America
5.2.1.1 United States (Value and Volume, 2012-2024)
5.2.1.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.1.2 Canada (Value and Volume, 2012-2024)
5.2.1.2.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.1.3 Rest of North America (Value and Volume, 2012-2024)
5.2.1.3.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.2 Europe
5.2.2.1 France (Value and Volume, 2012-2024)
5.2.2.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.2.2 Germany (Value and Volume, 2012-2024)
5.2.2.2.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.2.3 Italy (Value and Volume, 2012-2024)
5.2.2.3.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.2.4 Spain (Value and Volume, 2012-2024)
5.2.2.4.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.2.5 United Kingdom (Value and Volume, 2012-2024)
5.2.2.5.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.2.6 Russia (Value and Volume, 2012-2024)
5.2.2.6.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.2.7 Rest of Europe (Value and Volume, 2012-2024)
5.2.2.7.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.3 Latin America
5.2.3.1 Mexico (Value and Volume, 2012-2024)
5.2.3.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.3.2 Brazil (Value and Volume, 2012-2024)
5.2.3.2.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.3.3 Rest of Latin America (Value and Volume, 2012-2024)
5.2.3.3.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.4 Asia-Pacific
5.2.4.1 Japan (Value and Volume, 2012-2024)
5.2.4.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.4.2 South Korea (Value and Volume, 2012-2024)
5.2.4.2.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.4.3 China (Value and Volume, 2012-2024)
5.2.4.3.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.4.4 India (Value and Volume, 2012-2024)
5.2.4.4.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.4.5 Australia (Value and Volume, 2012-2024)
5.2.4.5.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.4.6 Vietnam (Value and Volume, 2012-2024)
5.2.4.6.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.4.7 Malaysia (Value and Volume, 2012-2024)
5.2.4.7.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.4.8 Indonesia (Value and Volume, 2012-2024)
5.2.4.8.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.4.9 Philippines (Value and Volume, 2012-2024)
5.2.4.9.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.4.10 Thailand (Value and Volume, 2012-2024)
5.2.4.10.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.4.11 Rest of Asia-Pacific (Value and Volume, 2012-2024)
5.2.4.11.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.5 Middle East & Africa
5.2.5.1 Saudi Arabia (Value and Volume, 2012-2024)
5.2.5.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.5.2 Iran (Value and Volume, 2012-2024)
5.2.5.2.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.5.3 Egypt (Value and Volume, 2012-2024)
5.2.5.3.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.5.4 Oman (Value and Volume, 2012-2024)
5.2.5.4.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.5.5 South Africa (Value and Volume, 2012-2024)
5.2.5.5.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.5.6 Rest of Middle & Africa (Value and Volume, 2012-2024)
5.2.5.6.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
6 MARKET INDICATORS
6.1 Type 1 Diabetes Population (2012-2024)
6.2 Type 2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Novo Nordisk AS
7.1.2 Sanofi Aventis
7.1.3 Eli Lilly
7.1.4 Biocon
7.1.5 Julphar
7.1.6 Exir
7.1.7 SEDICO
7.1.8 Wockhardt
7.2 COMPANY SHARE ANALYSIS
7.2.1 Novo Nordisk AS
7.2.2 Sanofi Aventis
7.2.3 Eli Lilly
7.2.4 Others
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Product Type
Basal or Long-acting Insulins (Value and Volume, 2012-2024)
Lantus
Levemir
Toujeo
Tresiba
Basaglar
Insulin Glargine Biosimilars
Geography
North America
United States (Value and Volume, 2012-2024)
Basal or Long-acting Insulins (Value and Volume, 2012-2024)
Canada (Value and Volume, 2012-2024)
Basal or Long-acting Insulins (Value and Volume, 2012-2024)
Rest of North America (Value and Volume, 2012-2024)
Basal or Long-acting Insulins (Value and Volume, 2012-2024)
Europe
France (Value and Volume, 2012-2024)
Basal or Long-acting Insulins (Value and Volume, 2012-2024)
Germany (Value and Volume, 2012-2024)
Basal or Long-acting Insulins (Value and Volume, 2012-2024)
Italy (Value and Volume, 2012-2024)
Basal or Long-acting Insulins (Value and Volume, 2012-2024)
Spain (Value and Volume, 2012-2024)
Basal or Long-acting Insulins (Value and Volume, 2012-2024)
United Kingdom (Value and Volume, 2012-2024)
Basal or Long-acting Insulins (Value and Volume, 2012-2024)
Russia (Value and Volume, 2012-2024)
Basal or Long-acting Insulins (Value and Volume, 2012-2024)
Rest of Europe (Value and Volume, 2012-2024)
Basal or Long-acting Insulins (Value and Volume, 2012-2024)
Latin America
Mexico (Value and Volume, 2012-2024)
Basal or Long-acting Insulins (Value and Volume, 2012-2024)
Brazil (Value and Volume, 2012-2024)
Basal or Long-acting Insulins (Value and Volume, 2012-2024)
Rest of Latin America (Value and Volume, 2012-2024)
Basal or Long-acting Insulins (Value and Volume, 2012-2024)
Asia-Pacific
Japan (Value and Volume, 2012-2024)
Basal or Long-acting Insulins (Value and Volume, 2012-2024)
South Korea (Value and Volume, 2012-2024)
Basal or Long-acting Insulins (Value and Volume, 2012-2024)
China (Value and Volume, 2012-2024)
Basal or Long-acting Insulins (Value and Volume, 2012-2024)
India (Value and Volume, 2012-2024)
Basal or Long-acting Insulins (Value and Volume, 2012-2024)
Australia (Value and Volume, 2012-2024)
Basal or Long-acting Insulins (Value and Volume, 2012-2024)
Vietnam (Value and Volume, 2012-2024)
Basal or Long-acting Insulins (Value and Volume, 2012-2024)
Malaysia (Value and Volume, 2012-2024)
Basal or Long-acting Insulins (Value and Volume, 2012-2024)
Indonesia (Value and Volume, 2012-2024)
Basal or Long-acting Insulins (Value and Volume, 2012-2024)
Philippines (Value and Volume, 2012-2024)
Basal or Long-acting Insulins (Value and Volume, 2012-2024)
Thailand (Value and Volume, 2012-2024)
Basal or Long-acting Insulins (Value and Volume, 2012-2024)
Rest of Asia-Pacific (Value and Volume, 2012-2024)
Basal or Long-acting Insulins (Value and Volume, 2012-2024)
Middle East & Africa
Saudi Arabia (Value and Volume, 2012-2024)
Basal or Long-acting Insulins (Value and Volume, 2012-2024)
Iran (Value and Volume, 2012-2024)
Basal or Long-acting Insulins (Value and Volume, 2012-2024)
Egypt (Value and Volume, 2012-2024)
Basal or Long-acting Insulins (Value and Volume, 2012-2024)
Oman (Value and Volume, 2012-2024)
Basal or Long-acting Insulins (Value and Volume, 2012-2024)
South Africa (Value and Volume, 2012-2024)
Basal or Long-acting Insulins (Value and Volume, 2012-2024)
Rest of Middle & Africa (Value and Volume, 2012-2024)
Basal or Long-acting Insulins (Value and Volume, 2012-2024
Bioabsorbable Stents Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 118 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 118 pages
- Published: 07-06-2019
Market Overview
The global bioabsorbable stents market was valued at USD 112.14 million in 2018, and is estimated to be valued at USD 183.28 million in 2024, witnessing a CAGR of 8.53%. Factors that are driving the market include a high prevalence of cardiovascular diseases, steep increase in the aging population, and the expanding base of the obese population.
As per the report of the World Health Organization (WHO), it is seen that the number one cause of death across the world is cardiovascular disease. Furthermore, the WHO has estimated that in 2016, approximately 17.9 million people died due to cardiovascular diseases (CVDs) which represents 31% of the total global deaths, and 85% of these deaths were due to heart attack and stroke. As reported by the Australian Heart Foundation, cardiovascular disease (CVD) is a major cause of death in Australia, with 43,477 deaths being attributed to CVD in Australia in 2017. Cardiovascular disease kills one Australian every 12 minutes. Hence, this global rise in the prevalence of CVD is expected to fuel the market growth.
Scope of the Report
According to the report, the polymer-based or metal-based stents dissolve or get absorbed in the body, and are expected to overcome complications and risks associated with metallic stents.
Key Market Trends
Polymer-based Bioabsorbable Stents Sub-segment is Expected to hold its Highest Market Share in the Product Type Segment
In the product type segment of the market, polymer-based bioabsorbable stents are believed to have the largest market size and are expected to witness a CAGR of 8.95% in the forecast period.
Bioabsorbable stents (BAS)/polymer-based bioabsorbable stents are made of the materials that can completely dissolve or be absorbed in the body. These are used both in peripheral and coronary artery disease. Most of the bioabsorbable stents are made of polylactic acid that is a naturally dissolvable material. However, the polymer materials, such as polycarbonates, polyesters, corrodible metals, and bacterial-derived polymers are under investigation for developing the next-generation bioabsorbable stents. The risk of the in-stent restenosis using drug-eluting and metallic stents (DES) has raised the need for bioabsorbable stents. The BAS has a low rate of late-stent thrombosis (LST) and restenosis, which led to the acceptance of BAS for clinical purposes. The product Absorb GT1 Bioresorbable Vascular Scaffold System (BVS) from Abbott was the first absorbable stent for coronary artery disease that received FDA in 2016, and was commercially available in Europe from 2011. However, on September 14, 2017, Abbott announced the end of sales of the Absorb bioresorbable vascular scaffold, due to poor sales and safety concerns, which led to a strong negative impact on the market. However, owing to the increased significance of the same, this sub-segment is expected to register substantial growth in the coming future.
Europe Dominates the Market and is Expected to do the Same in the Forecast Period
Europe currently dominates the market for bioabsorbable stents and is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the increased usage of bioabsorbable stents. There is a rise in the usage because the region has a large number of people suffering from cardiovascular diseases and there is a huge demand for technologically advanced treatment options for the same.
Competitive Landscape
The bioabsorbable stents market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new products at affordable prices. Companies, like Boston Scientific Corporation, Arterius Limited, Elixir Medical Corporation, Kyoto Medical Planning Co. Ltd, and Terumo Corporation, hold the substantial share in the market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Introduction to Market Drivers and Restraints
4.3 Market Drivers
4.3.1 High Prevalence of Cardiovascular Diseases Globally
4.3.2 Steep Increase in Aging Population
4.3.3 Expanding Base of Obese Population
4.4 Market Restraints
4.4.1 Stringent Regulatory Scenario
4.4.2 High Device Cost
4.4.3 Safety Issues Related to Bioabsorbable Stents
4.5 Industry Attractiveness – Porter’s Five Forces Analysis
4.5.1 Threat of New Entrants
4.5.2 Bargaining Power of Buyers/Consumers
4.5.3 Bargaining Power of Suppliers
4.5.4 Threat of Substitute Products
4.5.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product
5.1.1 Polymer-based Bioabsorbable Stents
5.1.2 Metal-based Bioabsorbable Stents
5.2 By Application
5.2.1 Coronary Artery Disease
5.2.2 Peripheral Artery Disease
5.3 By Absorption Rate
5.3.1 Slow Absorption Rate
5.3.2 Fast Absorption Rate
5.4 By End User
5.4.1 Hospitals
5.4.2 Other End Users
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East & Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East & Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Boston Scientific Corporation
6.1.2 Arterius Limited
6.1.3 Elixir Medical Corporation
6.1.4 Kyoto Medical Planning Co. Ltd
6.1.5 Terumo Corporation
6.1.6 Abbott Laboratories Inc.
6.1.7 Amaranth Medical
6.1.8 Biotronik
6.1.9 Meril Life Sciences Pvt. Ltd
6.1.10 Reva Medical
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Product
Polymer-based Bioabsorbable Stents
Metal-based Bioabsorbable Stents
By Application
Coronary Artery Disease
Peripheral Artery Disease
By Absorption Rate
Slow Absorption Rate
Fast Absorption Rate
By End User
Hospitals
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Biobanks Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 116 pages | Published: 10-06-2019 |
- Healthcare
- Mordor Intelligence
- 116 pages
- Published: 10-06-2019
Market Overview
The major factors for the growth of the global biobanks market include the innovations in regenerative medicine, the growing incidence of chronic diseases, advances in drug discovery and development, and R&D funding and investments by government and non-governmental organizations. These factors are expected to a boost the growth of the market over the forecast period.
Regenerative medicine through stem cell technology is one of the important treatments for diseases, such as Alzheimer’s, diabetes, cancers, and rare genetic diseases. In order to benefit from the existing therapies, umbilical cord cells and other stem cells are preserved.
Stem cell practices are on the rise, globally, and are contributing to the development of new solutions for various diseases. Boston-based biotech start-up, Orig3n, is looking to build the largest and most diverse biobank, harnessing the power of induced pluripotent stem cell technology to accelerate regenerative medicine. Treatments for diseases, like muscular degeneration, using adult stem cells are now going into Phase 3 clinical trials in Japan. These successes are driving both the government and the private sector organizations into investing in more stem cell banks.
With the increase in awareness about stem cell therapies, there have been larger number of parents who are choosing umbilical cord banks for their children. There are a number of donor banks that are coming up as well. Biobanks not only aid in the therapies for genetic diseases, but also in medical research on rare genetic disorders. Increasing awareness about stem cell therapies and innovation in the field of regenerative medicine are driving the growth of the global biobank market.
Scope of the Report
As per the scope of the report, biobank is a biorepository, where various biomaterials (usually human specimens) are stored for research purpose. This study targets gaining a detailed overview of the market dynamics of the contemporary biobank market during the forecast period. It focuses on the need to develop strategic insights into the global and country-level markets, taking into consideration the demand for services and equipment in biobanks. The growth of this market is largely fueled by the increasing applications, increasing investments in R&D, technological advancements, and growing demand in the developing countries (China and India) of Asia-Pacific.
Key Market Trends
Cryogenic Storage Segment by Equipment is Expected to Account for the Largest Market Share During the Forecast Period
In biobanks, the cryogenic storage systems are basically used to store different life sciences materials at a very low temperature. The low temperature storage increases the longevity of the cells, while at the same time reducing the intensity of freezing damage. Various cryogenic storage devices are available that have been designed to allow storage of both liquid and vapor phase materials. The temperature in the cryogenic storage system is required to be maintained continuously. Currently, all demand is for automated cryogenic storage devices. This segment is further divided into refrigerators, ice machines, and freezers. With advanced storage and automated devices propelling the growth of the market, steady growth in the North American and European markets is expected.
North America Accounted for the Largest Share in the Global Market
North America is holds a major share in the global biobanks market, and it is expected to show a similar trend over the forecast period, without significant fluctuations. The United States has the largest expenditure for R&D and better healthcare infrastructure in the world. Different pharmaceutical/ biotech companies, academia, and research institutes are utilizing biobanks for the storage of DNA, RNA, tissue, serum, blood, plasma, cells, etc. According to the Hastings Center, a non-profit organization, 300 million biospecimens have been stored in the United States in various public and private biobanks. The market is in demand for the most advanced automated systems, and there is also a high adoption rate for new technology.
Competitive Landscape
The global biobanks market is moderately consolidated. Some of the segments are dominated by a few major players, while the other segments are distributed among multiple players. The market players are moreover, focusing on collaboration and partnership activities. For instance, BioLife Solutions and SAVSU collaborated to provide enhanced, cold-chain technologies for diabetes, lupus, pemphigus, and organ transplantation in October 2017.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Innovations in Regenerative Medicine
4.2.2 Growing Incidences of Chronic Diseases
4.2.3 Advances in Drug Discovery and Development
4.2.4 R&D Funding and Investments by Government and Non-governmental Organizations
4.3 Market Restraints
4.3.1 Regulatory Issues
4.3.2 Cost Constraints
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Equipment
5.1.1 Cryogenic Storage Systems
5.1.1.1 Refrigerators
5.1.1.2 Ice Machines
5.1.1.3 Freezers
5.1.2 Alarm Monitoring Systems
5.1.3 Other Equipment
5.2 Media
5.2.1 Optimized Media
5.2.2 Non-optimized Media
5.3 Services
5.3.1 Human Tissue Biobanking
5.3.2 Stem Cell Biobanking
5.3.3 Cord Banking
5.3.4 DNA/RNA Biobanking
5.3.5 Other Services
5.4 Application
5.4.1 Regenerative Medicine
5.4.2 Drug Discovery
5.4.3 Disease Research
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East & Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East & Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Atlanta Biologicals Inc.
6.1.2 Becton, Dickinson and Company
6.1.3 BioLifeSolutions Inc.
6.1.4 Chart Industries Inc.
6.1.5 Hamilton Company
6.1.6 Qiagen NV
6.1.7 Sigma-Aldrich Inc. (Merck KGaA)
6.1.8 STEMCELL Technologies Inc.
6.1.9 Thermo Fisher Scientific Inc.
6.1.10 VWR International LLC
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Equipment
Cryogenic Storage Systems
Refrigerators
Ice Machines
Freezers
Alarm Monitoring Systems
Other Equipment
Media
Optimized Media
Non-optimized Media
Services
Human Tissue Biobanking
Stem Cell Biobanking
Cord Banking
DNA/RNA Biobanking
Other Services
Application
Regenerative Medicine
Drug Discovery
Disease Research
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Bioinformatics Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 118 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 118 pages
- Published: 07-06-2019
Market Overview
The propelling factors for the growth of the global bioinformatics market include the increasing demand for nucleic acid and protein sequencing, increasing initiatives from government and private organizations, accelerating growth of proteomics and genomics, and increasing research on molecular biology and drug discovery. Owing to the aforementioned factors, the global bioinformatics market is expected to experience a boost during the forecast period.
Bioinformatics is gaining importance, as large amounts of data generated through techniques, like nucleic acid and protein sequencing, require data management and interpretation for future researches and medical purposes. Hence, increasing demand is expected to drive the bioinformatics market during the forecast period.
The demand for differentially expressed genes, computational epigenetics, meta-analysis of microarray data, gene network, systems biology requirements, and gene-associating studies, among others, has had a major impact on the growth of the global bioinformatics market.
Thus, technical advancements, along with the advent of the NGS technology, have helped in the development of bioinformatics tools for analyzing a great amount of data. This has contributed to the growth of the global bioinformatics market.
There is also little research that has been done in the field of bioinformatics to expedite decision-making in healthcare. Within clinical or medical informatics, there is a rich history of research on systems designed to help care providers and patients (healthcare consumers) and make optimal decisions surrounding diagnosis and management.
Scope of the Report
As per the scope of the report, bioinformatics is the application of computational technology to gather, store, analyze, and integrate biological data. This data is used to procure information and is applied to gene-based drug discovery and development, protein structure studies, and the determination of the therapeutic efficacy of drugs.
Key Market Trends
Personalized Medicine is the Segment under Application that is Expected to Grow the Fastest During the Forecast Period
Bioinformatics is an essential component in basic research and in the development of new concepts for diagnosis and therapy, as well as in clinical practice, in which these concepts are applied to treat patients. Some of the major drivers that help in the increasing demand for bioinformatics are, growing applications of bioinformatics in drug discovery and development and growing bioinformatics support in the development of personalized medicines and clinical diagnostics.
Asia-Pacific Holds the Fastest Growth and is Expected to Follow the Same Trend over the Forecast Period
A large number of healthcare investments in the Asia-Pacific region are expected to drive the bioinformatics market. Furthermore, the high adoption of IoT technologies in this sector is expected to impact market growth in the region positively. Key countries, including China and India, are expected to propel the bioinformatics market in this region mainly.
Competitive Landscape
Many pharmaceutical companies are minimizing drug discovery budgets, as they are shifting their focus from outsourcing of the software to developing in-house tools, thus allowing them to customize their required applications to meet their needs and increasing workflow efficiency. The major global players in the bioinformatics market include Illumina, Thermo Fisher Scientific, and Agilent Technologies, among others.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Demand for Nucleic Acid and Protein Sequencing
4.2.2 Increasing Initiatives from Governments and Private Organizations
4.2.3 Accelerating Growth of Proteomics and Genomics
4.2.4 Increasing Research on Molecular Biology and Drug Discovery
4.3 Market Restraints
4.3.1 Lack of Well-defined Standards and Common Data Formats for Integration of Data
4.3.2 Data Complexity Concerns and Lack of User-friendly Tools
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product and Services
5.1.1 Knowledge Management Tools
5.1.2 Bioinformatics Platform
5.1.2.1 Interventional/Surgical Simulators
5.1.2.2 Sequence Analysis Platform
5.1.2.3 Sequence Alignment Platform
5.1.2.4 Sequence Manipulation Platform
5.1.2.5 Structural and Functional Analysis Platform
5.1.2.6 Other Bioinformatics Platforms
5.1.3 Bioinformatics Services
5.1.3.1 Sequencing Services
5.1.3.2 Database and Management Services
5.1.3.3 Data Analysis
5.1.3.4 Other Bioinformatics Services
5.2 By Application
5.2.1 Microbial Genome
5.2.2 Gene Engineering
5.2.3 Drug Development
5.2.4 Personalized Medicine
5.2.5 Omics
5.2.6 Other Applications
5.3 By End User
5.3.1 Pharmaceutical
5.3.2 Animal Study
5.3.3 Agriculture
5.3.4 Forensic science
5.3.5 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Illumina Inc.
6.1.2 Life Technologies (Thermo Fischer Scientific)
6.1.3 Qiagen NV
6.1.4 Agilent Technologies
6.1.5 PerkinElmer
6.1.6 ABM
6.1.7 Accelrys Inc.
6.1.8 Geneva Bioinformatics SA
6.1.9 Ontoforce
6.1.10 Data4Cure
6.1.11 Life Map Sciences (Biotime)
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Product and Services
Knowledge Management Tools
Bioinformatics Platform
Interventional/Surgical Simulators
Sequence Analysis Platform
Sequence Alignment Platform
Sequence Manipulation Platform
Structural and Functional Analysis Platform
Other Bioinformatics Platforms
Bioinformatics Services
Sequencing Services
Database and Management Services
Data Analysis
Other Bioinformatics Services
By Application
Microbial Genome
Gene Engineering
Drug Development
Personalized Medicine
Omics
Other Applications
By End User
Pharmaceutical
Animal Study
Agriculture
Forensic science
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Biopharmaceuticals Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 114 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 114 pages
- Published: 07-06-2019
Market Overview
The global biopharmaceuticals market was valued at USD 237,250.8 million in 2018, and is estimated to be valued at USD 388,997.3 million in 2024, witnessing a CAGR of 8.59%. The market growth is attributed to the growing acceptance for biopharmaceuticals due to their ability to treat previously untreatable diseases, resulting in huge market demand for biopharmaceuticals.
Biopharmaceuticals offer several benefits, such as highly effective and potent action, fewer side effects, and the potential to actually cure diseases rather than merely treat the symptoms, which have significantly increased the demand for biopharmaceutical products.
Biopharmaceuticals have reduced the number of deaths due to cancer and HIV/AIDS in the past decade, which has led to an increase in the adoption of biopharmaceuticals in the global market.
Biopharmaceuticals have given an alternative to the previously less effective and sometimes unsafe treatments, and it allows clinicians to tailor treatments to the specific medical problems experienced by each patient.
Scope of the Report
For the scope of the report, the term biopharmaceutical refers to any biologically synthesized molecule that is used to treat or manage disorders.
Key Market Trends
Monoclonal Antibodies are Expected to have the Largest Market Size
Among the given segments, monoclonal antibodies are believed to have the largest market size. This can be attributed to the growing research done with the help of monoclonal antibodies. On the other hand, the recombinant enzymes segment is expected to show rapid growth during the forecast period.
Monoclonal antibodies (mAbs) find their application in the areas of cancer treatment. Their use is becoming prevalent in developed countries, such as the United States and the United Kingdom. The mAb drugs in oncology are gaining momentum and growing at a decent pace. The segment is dominating the market currently, and the trend is expected to be followed in the future.
The recombinant enzymes, such as Enterokinase, are gaining attraction because of their efficacy in the digestion of the dietary proteins. Over the years, 100% native protein sequences have been produced using Enterokinase. This application has improved the market scope for this particular enzyme in the recent years.
North America is Expected to Dominate the Biopharmaceuticals Market
North America currently dominates the market for biopharmaceuticals, and is expected to continue its stronghold for a few more years. Asia-Pacific is expected to increase its market share in the future owing to increase in the prevalence of diseases, such as diabetes and cancer, along with the regulatory framework that is feasible for the approval of biopharmaceuticals in the region. The United States holds the majority of the market in the North American region; this is due to the increasing prevalence of chronic diseases. In addition, there is a rise in per capita health expenditure in the country that is expected to increase over the forecast period, owing to the decrease in the unemployment rate.
Competitive Landscape
The biopharmaceuticals market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancement and product innovation, mid-size to smaller companies are increasing their market presence by introducing new products with less prices. Companies, like Amgen Inc., Eli Lily & Company, Johnson & Johnson, and Pfizer Inc. hold a significant share in the biopharmaceuticals market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Acceptance for Biopharmaceuticals
4.2.2 Ability of Biopharmaceuticals to Treat Previously Untreatable Diseases
4.2.3 Huge Market Demand
4.3 Market Restraints
4.3.1 Increasing Demand for Affordable Biopharmaceuticals
4.3.2 High-end Manufacturing Requirements
4.3.3 Complicated and Cumbersome Regulatory Requirements
5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Monoclonal Antibodies
5.1.1.1 Anti Cancer Monoclonal Antibodies
5.1.1.2 Anti-inflammatory Monoclonal Antibodies
5.1.1.3 Other Monoclonal Antibodies
5.1.2 Recombinant Growth Factors
5.1.2.1 Erythropoietin
5.1.2.2 Granulocyte Colony Stimulating Factor
5.1.3 Purified Proteins
5.1.3.1 Leukemia Inhibitory Factor (LIF)
5.1.3.2 P53 Protein
5.1.3.3 P38 Protein
5.1.3.4 Other Purified Proteins
5.1.4 Recombinant Proteins
5.1.4.1 Serum Albumin
5.1.4.2 Amyloid Protein
5.1.4.3 Defensin
5.1.4.4 Transferrin
5.1.5 Recombinant Hormones
5.1.5.1 Recombinant Hormones
5.1.5.2 Recombinant Insulin
5.1.5.3 Other Recombinant Hormones
5.1.6 Vaccines
5.1.6.1 Recombinant Vaccines
5.1.6.1.1 Cancer Vaccines
5.1.6.1.2 Malaria Vaccines
5.1.6.1.3 Ebola Vaccine
5.1.6.1.4 Hepatitis-b Vaccine
5.1.6.1.5 Tetanus Vaccine
5.1.6.1.6 Diptheria Vaccine
5.1.6.1.7 Cholera Vaccine
5.1.6.1.8 Other Vaccines
5.1.6.2 Conventional Vaccines
5.1.6.2.1 Polio Vaccine
5.1.6.2.2 Pox Vaccine
5.1.6.2.3 Other Conventional Vaccines
5.1.6.3 Recombinant Enzymes
5.1.6.3.1 Enterokinase
5.1.6.3.2 Cyclase
5.1.6.3.3 Caspase
5.1.6.3.4 Cathepsin
5.1.6.4 Cell and Gene Therapies
5.1.6.4.1 Allogeneic Products
5.1.6.4.2 Autologous Products
5.1.6.4.3 Acellular Products
5.1.6.5 Other Product Types
5.1.6.5.1 Blood Factors
5.1.6.5.2 Other Product Types
5.1.7 Synthetic Immunomodulators
5.1.7.1 Cytokines, Interferones, Interleukins
5.1.7.2 Tumor Necrosis Factor (TNF)
5.2 By Therapeutic Application
5.2.1 Oncology
5.2.2 Inflammatory and Infectious Diseases
5.2.3 Autoimmune Disorders
5.2.4 Metabolic Disorders
5.2.5 Hormonal Disorders
5.2.6 Disease Prevention
5.2.7 Cardiovascular Diseases
5.2.8 Neurological Diseases
5.2.9 Other Diseases
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 United Kingdom
5.3.2.2 Germany
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia Pacific
5.3.3.1 India
5.3.3.2 China
5.3.3.3 Japan
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbvie Inc.
6.1.2 Amgen Inc.
6.1.3 Bristol-Myers Squibb Company
6.1.4 Eli Lily & Co.
6.1.5 Johnson & Johnson
6.1.6 Novartis AG
6.1.7 Novo Nordisk Inc.
6.1.8 Pfizer Inc.
6.1.9 GlaxoSmithKline PLC
6.1.10 Roche Holding AG
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Product Type
Monoclonal Antibodies
Anti Cancer Monoclonal Antibodies
Anti-inflammatory Monoclonal Antibodies
Other Monoclonal Antibodies
Recombinant Growth Factors
Erythropoietin
Granulocyte Colony Stimulating Factor
Purified Proteins
Leukemia Inhibitory Factor (LIF)
P53 Protein
P38 Protein
Other Purified Proteins
Recombinant Proteins
Serum Albumin
Amyloid Protein
Defensin
Transferrin
Recombinant Hormones
Recombinant Hormones
Recombinant Insulin
Other Recombinant Hormones
Vaccines
Recombinant Vaccines
Cancer Vaccines
Malaria Vaccines
Ebola Vaccine
Hepatitis-b Vaccine
Tetanus Vaccine
Diptheria Vaccine
Cholera Vaccine
Other Vaccines
Conventional Vaccines
Polio Vaccine
Pox Vaccine
Other Conventional Vaccines
Recombinant Enzymes
Enterokinase
Cyclase
Caspase
Cathepsin
Cell and Gene Therapies
Allogeneic Products
Autologous Products
Acellular Products
Other Product Types
Blood Factors
Other Product Types
Synthetic Immunomodulators
Cytokines, Interferones, Interleukins
Tumor Necrosis Factor (TNF)
By Therapeutic Application
Oncology
Inflammatory and Infectious Diseases
Autoimmune Disorders
Metabolic Disorders
Hormonal Disorders
Disease Prevention
Cardiovascular Diseases
Neurological Diseases
Other Diseases
Geography
North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Spain
Rest of Europe
Asia Pacific
India
China
Japan
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America